quinta-feira, 12 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 19, 2026

Defense Stock Face-Off: Lockheed Martin vs. Howmet Aerospace -- Which Is the Better Buy Right Now?

View original at nasdaq.com
Defense Stock Face-Off: Lockheed Martin vs. Howmet Aerospace -- Which Is the Better Buy Right Now? Key Points Lockheed Martin and Howmet Aerospace benefit from increased defense spending…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Howmet Aerospace is trading at more than 54 times forward earnings estimates, more than twice Lockheed's forward P/E ratio of 20.6, meaning much of Howmet's growth is already priced in

    60% confidence
  • Lockheed Martin's position as lead contractor for F-35 and major missile programs ensures steady cash flow largely insulated from traditional economic recessions

    60% confidence
  • The war in Iran will push Howmet's likely growth higher in 2026

    60% confidence
  • Lockheed Martin is a better buy than Howmet Aerospace due to steady income production, huge backlog, and greater diversity

    60% confidence
  • The Motley Fool Stock Advisor identified 10 best stocks for investors to buy now, and Lockheed Martin was not one of them

    60% confidence

Data points we hold from this source

Lockheed Martin Corporation · forward pe ratio20.6 ratio
Lockheed Martin Corporation · backlog194 USD
Lockheed Martin Corporation · quarterly dividend3.45 USD
Lockheed Martin Corporation · eps21.49 USD
Lockheed Martin Corporation · consecutive dividend increases23 years
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,565 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Defense Stock Face-Off: Lockheed Martin vs. Howmet Aerospace -- Which Is the Better Buy Right Now? — Source | Via News | pt.VIA.NEWS